The global healthcare industry is in the midst of an unprecedented transition. Nations are aging and increasingly facing a common set of morbidity and mortality drivers. They are also struggling to finance this growing burden. At the same time, the existing biopharm ROI model is challenged as never before. In the race to maintain growth on an ever expanding base, more compounds are attempting to address less well characterized biology. At the same time the generic pharmacy continues to improve as more blockbusters lose patent protection. With billions at stake, physicians and hospitals are being asked to justify their practices, and in turn life science companies are being asked to clinically justify their products.
And so unfolds the adventure that is the current state of the healthcare landscape. We at the Frankel Group feel privileged to be part of such an exciting industry, one that touches every member of our society. Within our walls, we have created a culture of curiosity and thought sharing, and are constantly discussing the benefits and risks of the opportunities healthcare stakeholders face. This blog has been developed as a way to share some of those thoughts, and engage in the debate regarding what the future holds for this fascinating industry.
The Current State of Pharmaceutical Industry Research and Development
Prepared by B. Frankel, D. Konciak, M. Berelowitz, L. Ratcliffe
Congratulations to Frankel Group authors David Gilman and Tyler Koop on the March 2011 IN VIVO article:
Growth Interrupted: Sustaining The Israeli Life Science Innovation Engine
(additional contributions by Tanya Nahvi, Dave Konciak and David Luckenbach)
